APRE Files 8-K on Material Definitive Agreement
Ticker: APRE · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Jan 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1.0 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
**APRE just signed a big deal, details pending, could be a game-changer.**
AI Summary
Aprea Therapeutics, Inc. (APRE) filed an 8-K on January 26, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates a significant new contract or partnership that could impact the company's future operations and financial health. For investors, this matters because material agreements often signal strategic shifts, potential revenue streams, or new collaborations, which could influence the stock's valuation depending on the nature and terms of the agreement.
Why It Matters
This filing signals a new, important business agreement for Aprea Therapeutics, which could significantly alter its operational strategy or financial outlook. Investors should monitor for details of this agreement as it could impact future revenue or expenses.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its potential positive or negative impact on the company.
Analyst Insight
Smart investors should await further details on this material definitive agreement to assess its potential impact on Aprea Therapeutics' financial performance and strategic direction before making any investment decisions.
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 26, 2024 (date) — date of earliest event reported
- APRE (company) — trading symbol on The NASDAQ Stock Market LLC
- The NASDAQ Stock Market LLC (company) — exchange where Aprea's common stock is registered
FAQ
What is the specific nature of the "Material Definitive Agreement" mentioned in the filing?
The filing states an "Entry into a Material Definitive Agreement" but does not provide specific details about the nature of the agreement, such as the parties involved, the terms, or the financial implications. Further disclosures would be needed for this information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 26, 2024, as indicated by the 'Date of Report (Date of earliest event reported)' section.
What is the trading symbol and exchange for Aprea Therapeutics, Inc. common stock?
Aprea Therapeutics, Inc. common stock trades under the symbol APRE on The NASDAQ Stock Market LLC, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' table.
What is the business address and phone number of Aprea Therapeutics, Inc.?
The business address for Aprea Therapeutics, Inc. is 3805 Old Easton Road, Doylestown, PA 18902, and their telephone number is (617) 463-9385, according to the filing's business address section.
What is the purpose of an 8-K filing related to a "Material Definitive Agreement"?
An 8-K filing is used to announce major events that shareholders should know about. Reporting an "Entry into a Material Definitive Agreement" signifies that the company has entered into a legally binding contract that is significant enough to potentially impact its financial condition or operations, requiring public disclosure.
Filing Stats: 1,008 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-01-26 07:13:27
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The NASDAQ Stock Mar
- $1.0 million — ng an aggregate offering price of up to $1.0 million (the "Shares") during the term of the S
Filing Documents
- tm244107d3_8k.htm (8-K) — 33KB
- 0001104659-24-006976.txt ( ) — 203KB
- apre-20240126.xsd (EX-101.SCH) — 3KB
- apre-20240126_lab.xml (EX-101.LAB) — 33KB
- apre-20240126_pre.xml (EX-101.PRE) — 22KB
- tm244107d3_8k_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On January 26, 2024, Aprea Therapeutics, Inc. (the "Company") entered into an at the market offering agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC (the "HCW"). Under the Sales Agreement, the Company may offer and sell its common stock, par value $0.001 per share ("Common Stock"), from time to time having an aggregate offering price of up to $1.0 million (the "Shares") during the term of the Sales Agreement through or to HCW as sales agent or principal. The Company has filed a prospectus supplement relating to the offer and sale of the Shares pursuant to the Sales Agreement. The offering and sale of the Shares will be made pursuant to the Company's Registration Statement on Form S-3, filed with the Securities and Exchange Commission (the "SEC") on January 26, 2024. The Shares may be offered only by means of a prospectus forming a part of the Registration Statement. The Company intends to use the net proceeds from the offering, if any, for general corporate purposes, including for preclinical studies and clinical trials and the advancement of our product candidates. The Company is not obligated to sell any Shares pursuant to the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, HCW will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations, to sell Shares from time to time based upon the Company's instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. Under the Sales Agreement, HCW may sell Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Sales Agreement may be terminated by either party providing notice, subject to the limitations set forth in the Sales Agreeme
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 At the Market Offering Agreement dated as of January 26, 2024, between Aprea Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 to the Company's Registration Statement of Form S-3, filed with the Securities and Exchange Commission on January 26, 2024). 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: January 26, 2024 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer